Coherus BioSciences, Inc. Stock price

Equities

CHRS

US19249H1032

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 02:48:06 2024-03-28 pm EDT 5-day change 1st Jan Change
2.435 USD +0.62% Intraday chart for Coherus BioSciences, Inc. -2.79% -26.73%
Sales 2024 * 262M Sales 2025 * 357M Capitalization 273M
Net income 2024 * -69M Net income 2025 * -20M EV / Sales 2024 * 2.07 x
Net Debt 2024 * 268M Net Debt 2025 * 286M EV / Sales 2025 * 1.56 x
P/E ratio 2024 *
-4.4 x
P/E ratio 2025 *
-22.5 x
Employees 306
Yield 2024 *
-
Yield 2025 *
-
Free-Float 95.95%
More Fundamentals * Assessed data
Dynamic Chart
1 day+5.22%
1 week-2.42%
Current month+6.14%
1 month-7.63%
3 months-10.04%
6 months-39.04%
Current year-27.33%
More quotes
1 week
2.26
Extreme 2.26
2.49
1 month
2.05
Extreme 2.05
2.64
Current year
1.93
Extreme 1.925
3.70
1 year
1.43
Extreme 1.4301
8.65
3 years
1.43
Extreme 1.4301
19.32
5 years
1.43
Extreme 1.4301
23.91
10 years
1.43
Extreme 1.4301
38.10
More quotes
Managers TitleAgeSince
Chief Executive Officer 68 10-08-31
Director of Finance/CFO 46 21-02-28
Chief Tech/Sci/R&D Officer - 21-11-30
Members of the board TitleAgeSince
Director/Board Member 52 21-01-04
Director/Board Member 70 11-12-31
Director/Board Member 46 14-04-30
More insiders
Date Price Change Volume
24-03-28 2.436 +0.66% 1 011 128
24-03-27 2.42 +5.22% 2,583,955
24-03-26 2.3 +0.88% 4,936,909
24-03-25 2.28 -2.15% 1,921,134
24-03-22 2.33 -7.17% 2,085,061

Delayed Quote Nasdaq, March 27, 2024 at 04:00 pm EDT

More quotes
Coherus BioSciences, Inc. is a commercial-stage biopharmaceutical company. The Company is focused on the research, development and commercialization of immunotherapies to treat cancer. Its immuno-oncology pipeline includes multiple antibody immunotherapy candidates focused on enhancing the innate and adaptive immune responses to enable an immunologic response and enhance outcomes for patients with cancer. Casdozokitug is an anti-IL-27 antibody being evaluated in two ongoing clinical studies: a Phase I/II study in advanced solid tumors and a Phase II study in hepatocellular carcinoma. CHS-114 is an ADCC-enhanced anti-CCR8 antibody in a Phase I/II study as a monotherapy in patients with advanced solid tumors. CHS-1000 is a preclinical candidate targeting immune-suppressive mechanisms via pathway ILT4. It markets LOQTORZI (toripalimab-tpzi), a next generation PD-1 inhibitor, UDENYCA (pegfilgrastim-cbqv), a biosimilar of Neulasta, and YUSIMRY (adalimumab-aqvh), a biosimilar of Humira.
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C-
More Ratings
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
2.42 USD
Average target price
7.8 USD
Spread / Average Target
+222.31%
Consensus
  1. Stock
  2. Equities
  3. Stock Coherus BioSciences, Inc. - Nasdaq